KALA BIO, Inc.
KALA
$0.57
$0.023.00%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 17.80M | 20.78M | 23.63M | 17.97M | 17.84M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 24.41M | 33.56M | 42.41M | 41.64M | 40.55M |
| Operating Income | -24.41M | -33.56M | -42.41M | -41.64M | -40.55M |
| Income Before Tax | -10.08M | -19.65M | -26.98M | -35.84M | -37.23M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -10.08 | -19.65 | -26.98 | -35.84 | -37.23 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -10.08M | -19.65M | -26.98M | -35.84M | -37.23M |
| EBIT | -24.41M | -33.56M | -42.41M | -41.64M | -40.55M |
| EBITDA | -24.07M | -33.23M | -42.09M | -41.31M | -40.28M |
| EPS Basic | -72.45 | -136.77 | -207.13 | -296.90 | -339.90 |
| Normalized Basic EPS | -81.76 | -121.23 | -165.10 | -199.91 | -208.76 |
| EPS Diluted | -72.45 | -136.77 | -207.13 | -296.90 | -339.90 |
| Normalized Diluted EPS | -81.76 | -121.23 | -165.10 | -199.91 | -208.76 |
| Average Basic Shares Outstanding | 12.34M | 12.40M | 651.70K | 491.90K | 443.70K |
| Average Diluted Shares Outstanding | 12.34M | 12.40M | 651.70K | 491.90K | 443.70K |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |